We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 21, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Combinations comprising mtor inhibitors for treating cancer
METHOD OF TREATING CANCER
PREDICTION OF TREATMENT RESPONSE TO JAK/STAT INHIBITOR
PHARMACEUTICAL COMBINATIONS OF A PI3K INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT
COMBINATION THERAPY FOR TREATING CANCER
Combination of pazopanib and topotecan